Alacris Receives German Innovation Award 2015
Berlin, 28th April 2015 - Alacris Theranostics GmbH announced today that they have been awarded the highly renowned German Innovation Award 2015.
Alacris Theranostics received the award in the category Medium-Sized Enterprises for ModCellTM, an innovative system biology-based modelling approach for personalised diagnostics, therapy and drug stratification with an initial focus on cancer. ModCellTM can predict potential effects and side effects of treatments on the basis of a detailed molecular analysis of the patient's tumor to support physicians in their decision making for an optimized therapy for each individual patient (currently in a clinical trial). In addition, ModCellTM can be used in both, biomarker identification and for the development and repositioning of drugs. By simulating drug activity in "virtual clinical trials", ModCellTM allows for a faster, more efficient drug development and approval process.
The unique feature of ModCellTM is the use of a systems biology model in the field of personalised medicine which is significantly different from statistical, correlative approaches, in most cases based only on single or multiple biomarkers. The analysis of individual biomarkers allows only examination of a partial aspect of the disease. ModCellTM however, generates a computer model of a "virtual patient" on the basis of analysing the totality of the biological data and therefore helps to identify individualised, promising treatment strategies for cancer patients.
"We are delighted that the jury of the German Innovation Award has honoured our innovative ModCellTM modelling approach," commented Bodo Lange, PhD, CEO of Alacris Theranostics GmbH. "The award is an important recognition of our approach and our work. This prize further encourages us to continuously develop and improve ModCellTM for achieving the best possible treatment for patients in the fight against cancer."
Alacris has established its own state-of-the-art Next Generation Sequencing Laboratory in Berlin with the appropriate sequencing and data analysis capabilities in order to generate data for the modelling of patients and tumours. With the development and commercialisation of this innovation in personalised healthcare, Alacris also attracts highly qualified international young scientists to the Berlin area. Berlin plays an important role as an attractive location for researchers, companies, founders and consequently investors.
About German Innovation Award
In 2010, Accenture, EnBW, Evonik and Wirtschaftswoche jointly formed the initiative "The German Innovation Award" to reward German companies with outstanding, pioneering innovations that have the potential to change business and markets. The prize is awarded in three categories to large companies, medium sized enterprises and start-ups. In addition to product innovations and innovative business models, the jury also considered processes, services and outstanding organisational and marketing innovations.
About Alacris Theranostics GmbH
Berlin-based Alacris Theranostics (www.alacris.de), a spin-off from the Max Planck Institute for Molecular Genetics, develops new approaches in personalised medicine for cancer patient diagnosis, treatment and drug stratification. The Company is applying the systems biology approach ModCellTM to provide a "Virtual Patient" model based on genome and transcriptome information obtained by next generation sequencing, mutation and drug databases as well as complex pathway information. This "Virtual Patient" model can predict the effects of drug treatment and optimised combinatory treatments to provide the means for truly personalised medicine approaches. In addition, Alacris' "Virtual Clinical Trials" system enables the in silico analysis of drugs, thus identifying stratified patient groups with particular genetic and molecular profiles that could be targeted by a drug to allow more efficient drug development and approval.
# # #
Contact:
Alacris Theranostics GmbH
Dr Bodo Lange, CEO
Fabeckstrasse 60-62
D-14195 Berlin
Germany
Phone: + 49 30 8431 22 510
Email: info@alacris.de
www.alacris.de
MC Services AG
Anne Hennecke, Managing Partner
Tel.: +49 211 529 252 22
Email: anne.hennecke@mc-services.eu
Help employers find you! Check out all the jobs and post your resume.
Alacris Theranostics received the award in the category Medium-Sized Enterprises for ModCellTM, an innovative system biology-based modelling approach for personalised diagnostics, therapy and drug stratification with an initial focus on cancer. ModCellTM can predict potential effects and side effects of treatments on the basis of a detailed molecular analysis of the patient's tumor to support physicians in their decision making for an optimized therapy for each individual patient (currently in a clinical trial). In addition, ModCellTM can be used in both, biomarker identification and for the development and repositioning of drugs. By simulating drug activity in "virtual clinical trials", ModCellTM allows for a faster, more efficient drug development and approval process.
The unique feature of ModCellTM is the use of a systems biology model in the field of personalised medicine which is significantly different from statistical, correlative approaches, in most cases based only on single or multiple biomarkers. The analysis of individual biomarkers allows only examination of a partial aspect of the disease. ModCellTM however, generates a computer model of a "virtual patient" on the basis of analysing the totality of the biological data and therefore helps to identify individualised, promising treatment strategies for cancer patients.
"We are delighted that the jury of the German Innovation Award has honoured our innovative ModCellTM modelling approach," commented Bodo Lange, PhD, CEO of Alacris Theranostics GmbH. "The award is an important recognition of our approach and our work. This prize further encourages us to continuously develop and improve ModCellTM for achieving the best possible treatment for patients in the fight against cancer."
Alacris has established its own state-of-the-art Next Generation Sequencing Laboratory in Berlin with the appropriate sequencing and data analysis capabilities in order to generate data for the modelling of patients and tumours. With the development and commercialisation of this innovation in personalised healthcare, Alacris also attracts highly qualified international young scientists to the Berlin area. Berlin plays an important role as an attractive location for researchers, companies, founders and consequently investors.
About German Innovation Award
In 2010, Accenture, EnBW, Evonik and Wirtschaftswoche jointly formed the initiative "The German Innovation Award" to reward German companies with outstanding, pioneering innovations that have the potential to change business and markets. The prize is awarded in three categories to large companies, medium sized enterprises and start-ups. In addition to product innovations and innovative business models, the jury also considered processes, services and outstanding organisational and marketing innovations.
About Alacris Theranostics GmbH
Berlin-based Alacris Theranostics (www.alacris.de), a spin-off from the Max Planck Institute for Molecular Genetics, develops new approaches in personalised medicine for cancer patient diagnosis, treatment and drug stratification. The Company is applying the systems biology approach ModCellTM to provide a "Virtual Patient" model based on genome and transcriptome information obtained by next generation sequencing, mutation and drug databases as well as complex pathway information. This "Virtual Patient" model can predict the effects of drug treatment and optimised combinatory treatments to provide the means for truly personalised medicine approaches. In addition, Alacris' "Virtual Clinical Trials" system enables the in silico analysis of drugs, thus identifying stratified patient groups with particular genetic and molecular profiles that could be targeted by a drug to allow more efficient drug development and approval.
# # #
Contact:
Alacris Theranostics GmbH
Dr Bodo Lange, CEO
Fabeckstrasse 60-62
D-14195 Berlin
Germany
Phone: + 49 30 8431 22 510
Email: info@alacris.de
www.alacris.de
MC Services AG
Anne Hennecke, Managing Partner
Tel.: +49 211 529 252 22
Email: anne.hennecke@mc-services.eu
Help employers find you! Check out all the jobs and post your resume.